ReviewOncoimmunology2016
Myeloid cells in the tumor microenvironment: Role of adenosine.
Review in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 67 citations in OpenAlex.
- Review
- Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression.Frontiers in immunology · 2026Article
- Review
- Rewiring T Cell Metabolism to Enhance CAR T Cell Function in Solid Tumor Microenvironments.Pharmaceutics · 2025Review
- Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).International journal of molecular medicine · 2025Review
- Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective.The FEBS journal · 2025Review
- Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management.Cancer management and research · 2025Review
- The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential.International journal of molecular sciences · 2024Review
- Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy.Cancer biology & medicine · 2024Review
- Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity.Cell reports. Medicine · 2024Article
- Metabolic engineering for optimized CAR-T cell therapy.Nature metabolism · 2024Review
- Myeloid-derived suppressor cells in cancer and cancer therapy.Nature reviews. Clinical oncology · 2024Review
- The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.International journal of molecular sciences · 2023Review
- Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine.International journal of molecular sciences · 2022Review
- Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.Journal of experimental & clinical cancer research : CR · 2022Article
- Emerging Targets in Clear Cell Renal Cell Carcinoma.Cancers · 2022Review
- Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.Acta pharmacologica Sinica · 2022Review
- Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.Expert opinion on therapeutic targets · 2022Review
- MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization.Scientific reports · 2022Article
- Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia. The effects of adenosine are mediated by four adenosine receptors, named A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.